Ulcerative Colitis

HW201877 enantiomer is the enantiomer of HW201877 (HY-174990) and is 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor with an IC₅₀ of 12.2 nM. HW201877 enantiomer can be used for the research of inflammatory bowel disease, idiopathic pulmonary fibrosis, ulcerative colitis, and Crohn's disease.

Minokitug is a humanized monoclonal antibody targeting the CCR2 protein. Minokitug can be used for the research of refractory/relapsed ulcerative colitis.

Zinc picolinate is an orally effective zinc supplement. Zinc picolinate reduces the expression of Hsp70, inhibits oxidative DNA damage, increases serum ALP activity, decreases MDA concentration, elevates SOD levels, and raises zinc concentrations in serum, whole body and plasma. Zinc picolinate does not alter copper and manganese contents in rainbow trout. Zinc picolinate exerts a protective effect against Acetic acid (HY-Y0319)-induced experimental colitis in Sprague Dawley rats. Zinc picolinate reduces uterine fibroid volume, alleviates colonic oxidative damage, relieves colonic inflammation, and enhances intestinal barrier integrity. Zinc picolinate can be used in research related to uterine fibroids, ulcerative colitis and chronic obstructive pulmonary disease.

Etamiphyllin (Etamiphylline) is a respiratory and cardiac stimulant. Etamiphyllin camsylate relaxes bronchial and bronchiolar smooth muscle to open airways, and increases cardiac output without elevating heart rate. The level of Etamiphyllin camsylate decreases in mice with ulcerative colitis, and it is positively correlated with *Bifidobacterium* and *Faecalibacterium*. Etamiphyllin camsylate can be applied to research related to chronic obstructive pulmonary disease, respiratory failure and ulcerative colitis.

Vitamin K2 is an orally active proliferation inhibitor. Vitamin K2 induces Autophagy and Apoptosis. Vitamin K2 reduces the levels of proinflammatory cytokines (such as IL-1β, TNF-α, and IL-6). Vitamin K2 inhibits cell growth in leukemia cells. Vitamin K2 can be used for the research of involutional osteoporosis, non-alcoholic fatty liver disease, ulcerative colitis, acute myeloid leukemia, myelodysplastic syndromes, and hepatocellular carcinoma.

Dexamethasone phosphate (Dexamethasone 21-phosphate) is a prodrug form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone phosphate is prepared by introducing a phosphate ester group to the hydroxyl group at position 21 of the Dexamethasone molecule. Dexamethasone phosphate inhibits LPS (HY-D1056)-induced degradation of IRAK-1 and IRAK-4, and blocks LPS-induced activation of TRAF6, p-TAK1 and p-JNK. Dexamethasone phosphate inhibits the secretion of RANTES, TGF-β1 and NO, promotes the production of MIP-1α and IL-10, and blocks microglial migration. Dexamethasone phosphate is almost completely converted to Dexamethasone in rat blood, and supports transdermal delivery via iontophoresis. Dexamethasone phosphate can be used in research related to steroid-dependent ulcerative colitis, chemotherapy-induced vomiting, allergic asthma and acute colitis (inflammatory bowel disease).

Afimkibart (PF-06480605; RVT-3101) is a humanized monoclonal antibody targeting TL1A (TNFSF15). Afimkibart blocks the TL1A‑DR3 signaling axis by neutralizing the TL1A ligand, inhibits the release of pro-inflammatory cytokines, suppresses NF-κB activation and IFN-γ production, and simultaneously attenuates fibroblast activation and fibrosis progression associated with this pathway. Afimkibart is applicable to research on immune inflammation-related conditions, such as ulcerative colitis.

DCM-KPV is a fluorescent probe targeting the human intestinal oligopeptide transporter PEPT1/SLC15A1 receptor (λ_ex=480 nm, λ_em=620-670 nm). DCM-KPV specifically binds to PepT1 via its KPV domain and mediates receptor-targeted internalization, thus effectively accumulating in the cytoplasm and nucleus of cells overexpressing this receptor. DCM-KPV has the advantages of long emission wavelength, high emission efficiency, low photobleaching, and negligible cytotoxicity. DCM-KPV maintains stable fluorescence intensity under continuous illumination, exhibiting extremely high live cell compatibility. DCM-KPV can specifically accumulate at colonic inflammatory sites through the intestinal mucosa, enabling direct non-invasive visual differentiation between chronic and acute ulcerative colitis groups and the normal group.

4-Guanidinobutanoic acid (Standard) is the analytical standard of 4-Guanidinobutanoic acid (HY-113286). This product is intended for research and analytical applications. 4-Guanidinobutanoic acid is a metabolite of arginine and an orally active SLC36A1/Hedgehog signaling pathway activator. 4-Guanidinobutanoic acid drives epithelial reprogramming, enhances intestinal stem cell function and goblet cell differentiation. 4-Guanidinobutanoic acid promotes the enrichment of Akkermansia muciniphila via mucus-dependent niche expansion, regulates intestinal homeostasis, and establishes a microbiota-host feedback loop. 4-Guanidinobutanoic acid exhibits anti-aging and healthspan-regulating properties. 4-Guanidinobutanoic acid can be used in research related to ulcerative colitis, amyotrophic lateral sclerosis, and Duchenne muscular dystrophy.

Cisapride-d₆ (R51619-d₆) is the deuterated-labeled Cisapride (HY-14149). Cisapride (R 51619) is an orally active, selective 5-HT₄ receptor agonist with an EC₅₀ of 140 nM. Cisapride also acts as an hERG potassium channel blocker with an IC₅₀ of 9.4 nM. Cisapride exerts gastrointestinal prokinetic effects by activating 5-HT₄ receptors, but it also blocks the hERG potassium channel responsible for the repolarization phase of cardiac action potentials, delaying repolarization and thus prolonging the action potential duration. Cisapride can be used in research related to gastrointestinal dysfunction, gastroesophageal reflux disease, functional dyspepsia, chronic gastritis, gastroparesis, ulcerative colitis and necrotizing enterocolitis.

Cisapride-¹³C,d₃ (R 51619-¹³C,d₃) is the deuterated, ¹³C-labeled Cisapride (HY-14149). Cisapride (R 51619) is an orally active, selective 5-HT₄ receptor agonist with an EC₅₀ of 140 nM. Cisapride also acts as an hERG potassium channel blocker with an IC₅₀ of 9.4 nM. Cisapride exerts gastrointestinal prokinetic effects by activating 5-HT₄ receptors, but it also blocks the hERG potassium channel responsible for the repolarization phase of cardiac action potentials, delaying repolarization and thus prolonging the action potential duration. Cisapride can be used in research related to gastrointestinal dysfunction, gastroesophageal reflux disease, functional dyspepsia, chronic gastritis, gastroparesis, ulcerative colitis and necrotizing enterocolitis.

Zotemtegrast (LY-4268989; MORF-057) is an orally active integrin α4β7 antagonist. Zotemtegrast is applicable to research related to inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.

Bisdemethoxycurcumin is an orally effective curcuminoid. Bisdemethoxycurcumin downregulates pro-inflammatory cytokines in macrophages by inhibiting the phosphorylation of PI3K/Akt and p38 MAPK. Bisdemethoxycurcumin relieves autophagy inhibition and promotes lipophagy to clear vascular smooth muscle foam cells by inhibiting the PDK1/Akt/mTOR pathway. Bisdemethoxycurcumin activates the cAMP/Epac/AMPKα axis and the NRF2/HO-1 antioxidant axis, thereby indirectly inhibiting the phosphorylation of NF-κB p65 and pro-inflammatory outputs such as IL-1β/IL-6/TNF-α, so as to alleviate pulmonary oxidative stress, inflammatory infiltration and pulmonary edema. Bisdemethoxycurcumin blocks NLRP3-mediated pyroptosis and protects cartilage extracellular matrix degradation by activating NRF2/HO-1. Bisdemethoxycurcumin also exerts a synergistic effect with potassium iodide against Candida.

PADI4_11 is an isoform-selective, allosteric PADI4 activator with a K_d of 457 nM. PADI4_11 enters cells via active transport, does not induce cytotoxicity or membrane damage, and serves as a tool for investigating the regulation, function and cellular reprogramming of PADI4. PADI4_11 can be used in studies related to rheumatoid arthritis and ulcerative colitis.

STING-IN-19 is a STING inhibitor with a K_d value of 2.31 μM for human STING. STING-IN-19 inhibits the activation of TBK1 and IRF3 by binding to STING, thereby suppressing the activation of downstream signaling pathways. STING-IN-19 reduces the levels of key inflammatory cytokines IL-1β, IL-6 and TNF-α in colonic tissues and serum of mice with ulcerative colitis. STING-IN-19 can be used in studies related to ulcerative colitis.

β5i-IN-2 is a potent, selective, and orally active inhibitor of the immunoproteasome β5i subunit, with an IC₅₀ of 0.08 μM against human β5i. β5i-IN-2 inhibits LPS (HY-D1056)- and IFN-γ-induced expression of IL-1β, IL-6, and TNF-α, and suppresses the JNK, ERK, and NF-κB signaling pathways. β5i-IN-2 can be used in research related to rheumatoid arthritis and ulcerative colitis.

Urease-IN-25 (Compound 10a) is a urease inhibitor with an IC₅₀ value of 0.50 μM against jack bean urease. Urease-IN-25 can be used in the research of Helicobacter pylori infection, chronic gastritis, peptic ulcer disease, gastric cancer, mucosa-associated lymphoid tissue lymphoma, and other conditions.

GPR43 agonist 1 is a selective, orally active GPR43 agonist. GPR43 agonist 1 downregulates the activity of NF-κB. GPR43 agonist 1 can be used in studies of acute colitis.

Anti-inflammatory agent 117 is an orally active anti-inflammatory agent and c-Kit kinase inhibitor with an IC₅₀ of 15.2 μM. Anti-inflammatory agent 117 blocks the NF-κB signaling pathway and inhibits the release of IL-6. Anti-inflammatory agent 117 exhibits anti-inflammatory effects in mouse models of acute lung injury, sepsis and ulcerative colitis. Anti-inflammatory agent 117 can be used in research related to acute lung injury, sepsis and ulcerative colitis.

TYY-31 is an orally active, selective S1PR1 agonist with an EC₅₀ of 1.13 pM. TYY-31 promotes the phosphorylation of ERK1/2. TYY-31 exerts anti-inflammatory and immunosuppressive effects, ameliorates DSS-induced colitis in mice, and reduces peripheral blood lymphocyte counts in mice in a dose-dependent manner. TYY-31 can be used for the research of ulcerative colitis.